Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel α4β2 nicotinic acetylcholine receptor selective agonists

Journal of Medicinal Chemistry

Volumn 50, Issue 22, 2007, Pages 5493-5508

  Ji, Anguo ^a   Schrimpf, Michael R ^a   Sippy, Kevin B ^a   Bunnelle, William H ^a   Li, Tao ^a   Anderson, David J ^a   Faltynek, Connie ^a   Surowy, Carol S ^a   Dyhring, Tino ^b   Ahring, Philip K ^b   Meyer, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

^b NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5,6 DICHLOROPYRIDIN 3 YL) 3,6 DIAZABICYCLO[3.2.0]HEPTANE TOSYLATE; 3 (5,6 DIMETHYLPYRIDIN 3 YL) 3,6 DIAZABICYCLO[3.2.0]HEPTANE FUMARATE; 3 (6 CHLORO 5 METHYLPYRIDIN 3 YL) 3,6 DIAZABICYCLO[3.2.0]HEPTANE TOSYLATE; 3 (6 CHLOROPYRIDIN 3 YL) 3,6 DIAZABICYCLO[3.2.0]HEPTANE FUMARATE; 3,6 DIAZABICYCLO[3.2.0]HEPTANE DERIVATIVE; ALPHA4 BETA2 NICOTINIC RECEPTOR; ALPHA4BETA2 NICOTINIC RECEPTOR AGONIST; BROMINE DERIVATIVE; CHLORINE DERIVATIVE; DIANICLINE; EPIBATIDINE; FUMARIC ACID; ISPRONICLINE; MORPHINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; TEBANICLINE; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VARENICLINE;

ACETYLCHOLINE RELEASE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CALCIUM; CELL LINE; HEPTANES; HUMANS; LIGANDS; NICOTINIC AGONISTS; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35848962986     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070755h     Document Type: Article

References (76)

1. Frederics, E.; Christoph, T.; Buschmann, H. Anangesics and anti-pretics. In Pharmaceuticals; McGuire, J. L., Ed.; Wiely-VCH: Weinheim, 2000; Vol. 2, pp 341-434.
2. (a) Jain, K. K. A guide to drug evaluation for chronic pain. Emerging Drugs 2000, 5, 241-257.
3. (b) Raith, K.; Hochhaus, G. Drugs used in the treatment of opioid tolerance and physical dependence: A review. Int. J. Clin. Pharmcol. Ther. 2004, 42, 191-203.
4. (c) Lewis, J. H. Nonsteroidal anti-inflammatory drugs: Pathology and clinical presentation of hepatotoxicity. In Drug-Induced Liver Disease; Kaplowitz, N., DeLeve, L. D., Eds.; Marcel Dekker, Inc.: New York, 2003; pp 377-404.
5. (d) Mitchell, J. A.; Warner, T. D. COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs. Nat. Rev. Drug Discovery 2006, 5, 75-86.
6. (a) Kennedy, J. D. Neuropathic pain: Molecular complexity underlies continuing unmet medical need. J. Med. Chem. 2007, 50, 2547-2556.
7. (b) Siniscalco, D.; De Novellis, V.; Rossi, F.; Maione, S. Neuropathic pain: Is the end of suffering starting in the gene therapy? Curr. Drug Targets 2005, 6, 75-80.
8. (c) Blackburn-Munro, G.; Erichsen, H. K. Antiepileptics and the treatment of neuropathic pain: Evidence from animal models. Curr. Pharm. Des. 2005, 11, 2961-2976.
9. (d) Chizh, B. A.; Headley, P. M. NMDA antagonists and neuropathic pain - Multiple drug targets and multiple uses. Curr. Pharm. Des. 2005, 11, 2977-2994.
10. (e) Bell, R. F.; Dahl, J. B.; Moore, R. A.; Kalso, E. Peri-operative ketamine for acute post-operative pain: A quantitative and qualitative systematic review (Cochrane review). Acta Anaesth. Scand. 2005, 49, 1405-1428.
11. (f) Eaton, M. Cell therapy for neuropathic pain in spinal cord injuries. Exp. Opin. Biol. Ther. 2004, 4, 1861-1869.
12. (a) Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P.; Neuronal nicotinic acetylcholine receptors: Structure revelations, targets identifications, and therapeutic inspirations. J. Med. Chem. 2005, 48, 4705-4745.
13. (b) Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: The quest for selectivity. Curr. Med. Chem. 2004, 4, 299-334.
14. (c) Holladay, M. W.; Dart, M. J.; Lynch, J. K. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 1997, 40, 4169-4194.
15. Millar, N. S. Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem. Soc. Trans. 2003, 31, 869-874.
16. (a) Copeland, R. L., Jr.; Leggett, Y. A.; Kanaan, Y. M.; Taylor, R. E.; Tizabi, Y. Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: Implications for Parkinson's disease. Neurotoxic. Res. 2005, 8, 289-293.
17. (b) Rueter, L. E.; Anderson, D. J.; Briggs, C. A.; Donnelly-Roberts, D. L.; Gintant, G. A.; Gopalakrishnan, M.; Lin, N.-H.; Osinski, M. A.; Reinhart, G. A.; Buckley, M. J.; Martin, R. L.; McDermott, J. S.; Preusser, L. C.; Seifert, T. R.; Su, Z.; Cox, B. F.; Decker, M. W.; Sullivan, J. P. ABT-089: Pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 2004, 10, 167-182.
18. (c) Newhouse, P. A.; Potter, A.; Kelton, M.; Corwin, J. Nicotinic treatment of Alzheimer's disease. Biol. Psychiatry 2001, 49, 268-278.
19. (d) Ross, G. W.; Petrovitch, H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001, 18, 797-806.
20. (e) Lloyd, G. K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 2000, 292, 461-467.
21. (f) Potter, A.; Corwin, J.; Lang, J.; Piasecki, M.; Lenox, R.; Newhouse, P. A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmcology 1999, 142, 334-342.
22. (a) Bitner, R. S.; Nikkel, A. L.; Curzon, P.; Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Namovic, M.; Jacobs, I. C.; Meyer, M. D.; Decker, M. W. Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. 2000, 871, 66-74.
23. (b) Marubio, L. M.; del Mar Arroyo-Jimenez, M.; Cordero-Erausquin, M.; Lena, C.; Le Novere, N.; de Kerchove d'Exaerde, A.; Huchet, M.; Damaj, M. I.; Changeux, J. P. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature 1999, 398, 805-810.
24. Sullivan, J. P.; Bannon, A. W. Epibatidine: Pharmacological properties of a novel nicotinic acetylcholine receptor agonist and analgesic agent. CNS Drug Rev. 1996, 2, 21-39.
25. (a) Davis, L.; Pollock, L. J.; Stone, T. T. Visceral pain. Surg. Gynecol. Obstet. 1932, 55, 418-426.
26. (b) Tripathi, H. L.; Martin, B. R.; Aceto, M. D. Nicotine-induced antinociception in rats and mice: Correlation with nicotine brain levels. J. Pharmacol. Exp. Ther. 1982, 221, 91-96.
27. (c) Glennon, R. A. Nicotine and pain. Med. Chem. Res. 2004, 13, 74-77.
28. (a) Spande, T. F.; Garraffo, H. M.; Edwards, M. W.; Yeh, H. J. C.; Panel, L.; Daly, J. W. Epibatidiene: A novel (chloropyridyl)-azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J. Am. Chem. Soc. 1992, 114, 3475-3478.
29. (b) Badio, B.; Garraffo, H. M.; Spande, T. F.; Daly, J. W. Epibatidine: Discovery and definition as a potent analgesic and nicotinic agonist. Med Chem. Res. 1994, 4, 440-448.
30. (c) Badio, B.; Daly, J. W. Epibatidines: A potent analgesic and nicotinic agonist. Mol. Pharmacol. 1994, 45, 563-569.
31. (a) Dukat, M.; Damaj, M. I.; Glassco, W.; Dumas, D.; May, E. L.; Martin, B. R.; Glennon, R. A. Epibatidine: A very high affinity nicotinic receptor ligand. Med. Chem. Res. 1994, 4, 131-139.
32. (b) Qian, C.; Li, T.; Shen, T. Y.; Libertine-Garahan, L.; Eckman, J.; Biftu, T.; Ip, S. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 1993, 250, R13-R14.
33. (a) Parker, M. J.; Beck, A.; Luetje, C. W. Neuronal nicotinitic receptor β2 and α4 subunits confer large differences in agonist binding affinity. Mol. Pharmacol. 1998, 54, 1132-1139.
34. (b) Sullivan, J. P.; Briggs, C. A.; Donnelly-Roberts, D.; Brioni, J. D.; Radek, R. J.; McKenna, D. G.; Campbell, J. E.; Arneric, S. P.; Decker, M. W.; Bannon, A. W. ±-Epibatidine and differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. 1994, 4, 502-516.
35. Daly, J. W.; Garraffo, H. M.; Spande, T. F.; Decker, M. W.; Sullivan, J. P.; Williams, M. Alkaloids from frog skin: The discovery of epibatidine and the potential for developing novel non-opoid analgesics. Nat. Prod. Rep. 2000, 17, 131-135.
36. (a) Lynch, J. J.; Wade, C. L.; Mikusa, J. P.; Decker, M. W.; Honore, P. ABT-594 (a nicotinic acetylcholine agonist): Anti-allodynia in a rat chemotherapy-induced pain model. Eur. J. Pharmacol. 2005, 509, 43-48.
37. (b) Sorbera, L. A.; Revel, L.; Leeson, P. A.; Castañer, J. ABT-594. Drugs Future 2001, 26, 927-934.
38. (c) Holladay, M. W.; Wasicak, J. T.; Lin, N.-H.; He, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Decker, M. W.; Anderson, D. J.; Cambell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2- chloropyridine (ABT-594), a potent orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 1998, 41, 407-412.
39. (d) Decker, M. W.; Curzon, P.; Holladay, M. W.; Nikkel, A. L.; Bitner, R. S.; Bannon, A. W.; Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Williams, M.; Arneric, S. P. The role of neuronal nicotinic acetylcholine receptors in antinociception: Effects of ABT-594. J. Physiol. 1998, 92, 221-224.
40. (a) Kanne, D. B.; Tomizawa, M.; Durkin, K. A.; Casida, J. E. 6′-Methylpyrido[3,4-b]norhomotropane: Synthesis and outstanding potency in relation to the α4β2 nicotinic receptor pharmacophore model. Bioorg. Med. Chem. Lett. 2005, 15, 877-881.
41. (b) Glennon, R. A.; Dukat, M. α4β2 nACh receptor phamacophore models. Bioorg. Med. Chem. Lett. 2004, 14, 1841-1844.
42. (c) Glennon, R. A.; Dukat, M.; Liao, L. Musings on α4β2 nicotinic acetylcholine (nACh) receptor pharmacophore models. Curr. Top. Med. Chem. 2004, 4, 631-644.
43. (d) Sharpies, C. G. V.; Karig, G.; Simpson, G. L.; Spencer, J. A.; Wright, E.; Millar, N. S.; Wonnacott, S.; Gallagher, T. Synthesis and pharmacological characterizations of novel analogues of nicotinic acetylcholine receptor agonist (±)-UB-165. J. Med. Chem. 2002, 45, 3235-3245.
44. (e) Sheridan, R. P.; Nilakantan, R.; Nixon, J. S.; Venkataraghavan, R. The ensemble approach to distance geometry: Application to the nicotinic pharmacophore. J. Med. Chem. 1986, 29, 899-906.
45. (f) Beers, W. H.; Reich, E. Structure and activity of acetylcholine. Nature 1970, 228, 917-922.
46. (a) Tonstad, S. Varenicline for smoking cessation. Exp. Rev. Neurother. 2007, 7, 121-127.
47. (b) Rollema, H.; Chambers, L. K.; Coe, J. W.; Glowa, J.; Hurst, R. S.; Lebel, L. A.; Lu, Y.; Mansbach, R. S.; Mather, R. J.; Rovetti, C. C.; Sands, S. B.; Schaeffer, E.; Schulz, D. W.; Tingley, F. D.; Williams, K. E. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52, 985-994.
48. (c) Keating, G. M.; Siddiqui, M. A. A. Varenicline: A review of its use as an aid to smoking cessation therapy. CNS Drugs 2006, 20, 945-960.
49. (d) Mihalak, K. B.; Carroll, I.; Luetje, C. W. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharmacol. 2006, 70, 801-805.
50. Cohen, C.; Bergis, O. E.; Galli, F. A.; Lochead, W.; Jegham, S.; Biton, B.; Léonardon, J.; Avenet, P.; Sgard, F.; Besnard, F.; Graham, D.; Coste, A.; Oblin, A.; Curet, O.; Voltz, C.; Gardes, A.; Caille, D.; Perrault, G.; George, P.; Soubrié, P.; Scatton, B. SSR591813, a novel selective and partial α4β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. 2003, 306, 407-420.
51. (a) Dunbar, G. C.; Kuchibhatla, R. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J. Mol. Neurosci. 2006, 30, 169-172.
52. (b) Lippiello, P.; Letchworth, S. R.; Gatto, G. J.; Traina, V. M.; Bencherif, M. Ispronicline: A novel α4β2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J. Mol. Neurosci. 2006, 30, 19-20.
53. (c) Caldwell, W. S.; Dull, G. M.; Bhatti, B. S.; Hadimani, S. B.; Park, H.; Wagner, J. M.; Crooks, P. A.; Lippiello, P. M.; Bencherif, M. Preparation of aryl substituted olefinic amines and their use as cholinergic receptors agonists. PCT Int. Appl. WO 9965876, December 23, 1999.
54. (a) Audouze, K.; Oestergaard, N.; Elsebet, O.; Gunnar, M.; Ahring, P.; Jorgensen, T. D.; Peters, D.; Liljefors, T.; Balle, T. New ligands with affinity for the α4β2 subtype of nicotinic acetylcholine receptors, synthesis, receptor binding, and 3D-QSAR modeling. J. Med. Chem. 2006, 49, 3159-3171.
55. (b) Nielsen, S. F.; Nielsen, E. O.; Olsen, G. M.; Liljefors, T.; Peters, D. Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analyses. J. Med. Chem. 2000, 43, 2217-2226.
56. For racemic synthesis of 19, see (a) Jacquet, J.-P.; Bouzard, D.; Kiechel, J.-R.; Remuzon, P. Synthesis of a new bridged diamine, 3,6-diazabicyclo[3.2.0]heptane: Applications to the synthesis of quinolone antibacterials. Tetrahedron Lett. 1991, 32, 1565.
57. (b) Colon-Cruz, R.; Didiuk, M. T.; Duffy, E. M.; Garigipati, R. S.; Lau, W. F.; McDonald, W. S. Preparation of bicyclic diamines as CCR2 and CCR3 chemokine receptor antagonists for treating/preventing diseased associated with monocyte, lymphocyte or leukocyte accumulation. PCT Int. Appl. WO 2002070523, September 12, 2002.
58. Schenke, T.; Petersen, U. Preparation of 2,7-diazabicyclo[3.3.0]-octanes as intermediates for quinolone antibacterials. Eur. Pat. Appl. EP 393424, October 24, 1990.
59. Mzengeza, S.; Whitney, R. A. Asymmetric induction in nitrone cycloadditions: A total synthesis of acivicin by double asymmetric induction J. Org. Chem. 1988, 53, 4074-4081.
60. Ohta, N.; Makino, T.; Shimizu, S. Enantiomerically pure substituted oxaaza compounds, salts of the same, and processes for the preparation of both. U.S. Patent 6,423,843, July 23, 2002.
61. (a) Muci, A. R.; Buchwald, S. L. Practical palladium catalysts for C-N and C-O bond formation Top. Curr. Chem. 2002, 219, 131-209.
62. (b) Hartwig, J. F. Carbon-heteroatom bond-forming reductive eliminations of amines, ethers, and sulfides. Acc. Chem. Res. 1998, 31, 852-860.
63. Sonogashira, K.; Tohda, Y.; Hagihara, N. Convenient synthesis of acetylenes. Catalytic substitutions of acetylenic hydrogen with bromo alkenes, iodo arenes, and bromopyridines. Tetrahedron Lett. 1975, 16, 4467-4470.
64. Stille, J. K. The palladium-catalyzed cross-coupling reactions of organotin reagents with organic electrophiles Angew. Chem. Int. Ed. Engl. 1986, 25, 508-524.
65. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol. Pharmacol. 1995, 48, 280-287.
66. (b) Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 1992, 41, 31-37.
67. 3H]ABT-418: A novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 1995, 273, 1434-1441.
68. 3H]-Cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 1991, 39, 9-12.
69. Gribbon, P.; Sewing, A. Fluorescence readouts in HTS: No gain without pain? Drug Discovery Today 2003, 22, 1035-1043.
70. (a) Fitch, R. W.; Xiao, Y.; Kellar, K. J.; Daly, J. W. Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function. Proc. Natl. Acad. Sci. 2003, 100, 4909-4914.
71. (b) Kuntzweiler, T. A.; Arneric, S. P.; Donnelly-Roberts, D. L. Rapid assessment of ligand actions with nicotinic acetylcholine receptors using calcium dynamics and FLIPR. Drug Dev. Res. 1998, 44, 14-20.
72. (a) Boisbrun, M.; Jeannin, L.; Toupet, L.; Laronze, J.-Y. A convenient synthesis of indole-substituted 2-pyrrolidones and their cyclized derivatives. Eur. J. Org. Chem. 2000, 3051-3057.
73. (b) Bischofberger, N.; Waldmann, H.; Saito, T.; Simon, E. S.; Lees, W.; Bednarski, M. D.; Whitesides, G. M. Synthesis of analogs of 1,3-dihydroxyacetone phosphate and glyceraldehyde 3-phosphate for use in studies of fructose-1,6-diphosphate aldolase. J. Org. Chem. 1988, 53, 3457-3465.
74. Aggarwal, V. K.; Roseblade, S.; Alexander, R. The use of enantiomerically pure ketene dithioacetal bis(sulfoxides) in highly diastereoselective intramolecular nitrone cycloadditions. Application in the total synthesis of the β-amino acid (-)-cispentacin and the first asymmetric synthesis of cis-(3R,4R)-4-aminopyrrolidine-3-carboxylic acid. Org. Biomol. Chem. 2003, 1, 684-691.
75. (a) Okano, K.; Ibata, T. Preparation of (3S,4S)-3-amino-4- hydroxymethylpyrrolidines as intermediates for quinolone bactericides by diastereomeric salt formation. Jpn. Kokai Tokkyo Koho 2000, JP 2000026408.
76. Takemura, M.; Takahashi, H.; Sugita, K.; Kimura, K.; Miyauchi, R. Preparation of optically active (3S,4S)-3-amino-4- acyloxymethylpyrrolidines as materials for microbicide. Jpn. Kokai Tokkyo Koho 1999, JP 11292841.